20 articles
New research reveals how ฮฑ-ketoglutarate regulates AMPK synthesis, offering potential cancer therapy targets through energy stress.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact ฮฑ-helical TCR mimic with 9.5 nM affinity for a tumor antigen โ and near-perfect peptide specificity.
New research reveals how a metabolic enzyme fuels hepatocellular carcinoma progression through altered lipid synthesis pathways.
A newly discovered hepatic micropeptide suppresses liver cancer progression by jamming a key mitochondrial RNA processing complex.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
A landmark screen of approved kinase inhibitors reveals 94% of cancer mutations are already targetable โ and uncovers surprising new drug uses.
Scientists uncover how SCRN1 blocks ferroptosis in liver cancer, revealing new targets for treating drug-resistant hepatocellular carcinoma.
Novel nanoplatform delivers copper and iron ions to trigger both ferroptosis and cuproptosis in cancer cells.
Researchers develop monoclonal antibody that specifically inhibits heparanase, reducing tumor growth and metastasis in multiple cancer types.
New research shows how activating PKM2 enzyme enhances CD8 T cell function and improves anti-PD1 cancer therapy effectiveness.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
Scientists discover KLHL6 protein prevents immune cell dysfunction in tumors, offering new target for cancer immunotherapy.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer โ blocking it supercharges immunotherapy response.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
B7-H3-targeted therapy HS-20093 achieved 52% response rate in small cell lung cancer and 22% in non-small cell lung cancer patients.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
Pyrroloquinoline quinone has demonstrated anticancer activity in preclinical studies, but human cancer trials remain absent. Here's where the science stands.
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
